NCT01282138

Brief Summary

The purpose of this study was to evaluate ocular responses with different allergen provocation methods.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Dec 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 20, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 24, 2011

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2011

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

July 25, 2012

Completed
Last Updated

December 18, 2012

Status Verified

July 1, 2012

Enrollment Period

3 months

First QC Date

January 20, 2011

Results QC Date

June 20, 2012

Last Update Submit

December 16, 2012

Conditions

Keywords

Allergic conjunctivitis

Outcome Measures

Primary Outcomes (2)

  • Change From Baseline in Patient-Assessed Ocular Itching, Environmental Exposure Chamber (EEC), at 3 Hours

    As assessed by the participant after 3 hours in the EEC. Ocular itching was graded on a 0-4 scale, where 0=none, 1=tickling sensation involving one or more corners of the eye, 2=all over tickling sensation; 3=moderate continuous itching with desire to rub; 4=severe itching with irresistible urge to rub.

    Baseline, 3 hours

  • Change From Baseline in Patient-Assessed Ocular Itching, Conjunctival Allergen Provocation Test (CAPT), at 3 Hours

    As assessed by the participant after 3 hours of CAPT. Ocular itching was graded on a 0-4 scale, where 0=none, 1=tickling sensation involving one or more corners of the eye, 2=all over tickling sensation; 3=moderate continuous itching with desire to rub; 4=severe itching with irresistible urge to rub.

    Baseline, 3 hours

Study Arms (2)

Patanol

EXPERIMENTAL

One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.

Drug: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)

Tears Naturale II

PLACEBO COMPARATOR

One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.

Other: Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)

Interventions

One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.

Also known as: Patanol®
Patanol

One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.

Also known as: Tears Naturale II
Tears Naturale II

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • History of allergic conjunctivitis;
  • Active signs and symptoms of ocular allergies;

You may not qualify if:

  • History of dry eye;
  • Presence of ocular infection;
  • Presence of severe or serious ocular conditions;
  • Symptoms of allergic conjunctivitis;
  • Use of topical or systemic ocular medications as specified in protocol;
  • Ocular surgery or laser surgery within 6 months of study start;
  • Unwilling to discontinue contact lens wear 72 hours prior to Visit 1 and during study period;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Contact Alcon Call Center for Trial Locations

Fort Worth, Texas, 76134, United States

Location

MeSH Terms

Conditions

Conjunctivitis, Allergic

Interventions

Olopatadine HydrochlorideOphthalmic SolutionsDextransHypromellose DerivativesLubricant Eye Drops

Condition Hierarchy (Ancestors)

ConjunctivitisConjunctival DiseasesEye DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

DibenzoxepinsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsPharmaceutical SolutionsSolutionsPharmaceutical PreparationsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesSpecialty Uses of ChemicalsGlucansBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesCelluloseBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and AgricultureLubricants

Limitations and Caveats

This was a pilot study with a small number of subjects not adequately powered to detect treatment differences.

Results Point of Contact

Title
Head, Global Medical Affairs
Organization
Alcon Research

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 20, 2011

First Posted

January 24, 2011

Study Start

December 1, 2010

Primary Completion

March 1, 2011

Study Completion

March 1, 2011

Last Updated

December 18, 2012

Results First Posted

July 25, 2012

Record last verified: 2012-07

Locations